Abstract
We read with interest the letter by Drs. Wang-Gohrke and Chang-Claude regarding the association between a HER2 genetic polymorphism and breast cancer risk. In a case–control study conducted among German Caucasian women, Drs. Wang-Gohrke and Chang-Claude found that the Val allele of the HER2 (Val655Ile) polymorphism was associated with a twofold elevated risk of breast cancer among women who had a family history of breast cancer among their first-degree relatives. This positive association, however, was not observed among women without such a family history. These data suggest that a family history of breast cancer may modify the association between the HER2 polymorphism and the risk of breast cancer.

This publication has 2 references indexed in Scilit: